Works matching AU Tolcher, Anthony

Results: 57

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors.

Published in:

2017

By:

Tolcher, Anthony;
Berlin, Jordan;
Cosaert, Jan;
Kauh, John;
Chan, Emily;
Piha-Paul, Sarina;
Amaya, Alex;
Tang, Shande;
Driscoll, Kyla;
Kimbung, Richard;
Kambhampati, S.;
Gueorguieva, Ivelina;
Hong, David;
Tolcher, Anthony W;
Berlin, Jordan D;
Piha-Paul, Sarina A;
Kambhampati, S R Prasad;
Hong, David S

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Waring, Jeffrey;
Yang, Jianning;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Waring, Jeffrey F;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors.

Published in:

2015

By:

Tolcher, Anthony;
LoRusso, Patricia;
Arzt, Jennifer;
Busman, Todd;
Lian, Guinan;
Rudersdorf, Niki;
Vanderwal, Carol;
Kirschbrown, Whitney;
Holen, Kyle;
Rosen, Lee;
Tolcher, Anthony W;
Busman, Todd A;
Rudersdorf, Niki S;
Vanderwal, Carol Ann;
Holen, Kyle D;
Rosen, Lee S

Publication type:

journal article

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors.

Published in:

OncoImmunology, 2013, v. 2, n. 1, p. e23033-1, doi. 10.4161/onci.23033

By:

Vonderheide, Robert H.;
Burg, Jennifer M.;
Mick, Rosemarie;
Trosko, Jennifer A.;
Dongguang Li;
Naveed Shaik, M.;
Tolcher, Anthony W.;
Hamid, Omid

Publication type:

Article

Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.

Published in:

OncoTargets & Therapy, 2024, v. 17, p. 267, doi. 10.2147/OTT.S440979

By:

Yamamoto, Noboru;
Tolcher, Anthony;
Hafez, Navid;
Lugowska, Iwona;
Ramlau, Rodryg;
Macarulla, Teresa;
Geng, Junxian;
Li, Jian;
Teufel, Michael;
Märten, Angela;
LoRusso, Patricia

Publication type:

Article

Apoptosis: mechanisms and implications for cancer therapeutics.

Published in:

Targeted Oncology, 2006, v. 1, n. 4, p. 197, doi. 10.1007/s11523-006-0034-1

By:

Mita, Monica;
Mita, Alain;
Tolcher, Anthony

Publication type:

Article

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.

Published in:

2018

By:

Goss, Glenwood D.;
Vokes, Everett E.;
Gordon, Michael S.;
Gandhi, Leena;
Papadopoulos, Kyriakos P.;
Rasco, Drew W.;
Fischer, JuDee S.;
Chu, Katharine L.;
Ames, William W.;
Mittapalli, Rajendar K.;
Lee, Ho‐Jin;
Zeng, Jiewei;
Roberts‐Rapp, Lisa A.;
Loberg, Lise I.;
Ansell, Peter J.;
Reilly, Edward B.;
Ocampo, Christopher J.;
Holen, Kyle D.;
Tolcher, Anthony W.;
Lee, Ho-Jin

Publication type:

journal article

Dose determination for molecularly targeted therapies: Much Ado About Nothing.

Published in:

2017

By:

Tolcher, Anthony

Publication type:

Editorial

A Randomized Phase 2 Trial Comparing 3-Hour Versus 96-Hour Infusion Schedules of Paclitaxel for the Treatment of Metastatic Breast Cancer.

Published in:

Cancer (0008543X), 2010, v. 116, n. 4, p. 814, doi. 10.1002/cncr.24870

By:

Moulder, Stacy L.;
Holmes, Frankie A.;
Tolcher, Anthony W.;
Thall, Peter;
Broglio, Kristine;
Valero, Vicente;
Buzdar, Aman U.;
Arbuck, Susan G.;
Seidman, Andrew;
Hortobagyi, Gabriel N.

Publication type:

Article

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2024.1376551

By:

Shimizu, Toshio;
Powderly, John;
Abdul Razak, Albiruni;
LoRusso, Patricia;
Miller, Kathy D.;
Kao, Steven;
Kongpachith, Sarah;
Tribouley, Catherine;
Graham, Michelle;
Stoll, Brian;
Patel, Maulik;
Sahtout, Mohammad;
Blaney, Martha;
Leibman, Rachel;
Golan, Talia;
Tolcher, Anthony

Publication type:

Article

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

Published in:

2025

By:

Shimizu, Toshio;
Powderly, John;
Abdul Razak, Albiruni;
LoRusso, Patricia;
Miller, Kathy D.;
Kao, Steven;
Kongpachith, Sarah;
Tribouley, Catherine;
Graham, Michelle;
Stoll, Brian;
Patel, Maulik;
Sahtout, Mohammad;
Blaney, Martha;
Leibman, Rachel;
Golan, Talia;
Tolcher, Anthony

Publication type:

Correction Notice

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors.

Published in:

Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1376551

By:

Shimizu, Toshio;
Powderly, John;
Abdul Razak, Albiruni;
LoRusso, Patricia;
Miller, Kathy D.;
Kao, Steven;
Kongpachith, Sarah;
Tribouley, Catherine;
Graham, Michelle;
Stoll, Brian;
Patel, Maulik;
Sahtout, Mohammad;
Blaney, Martha;
Leibman, Rachel;
Golan, Talia;
Tolcher, Anthony

Publication type:

Article

Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer.

Published in:

Journal of Ovarian Research, 2013, v. 6, n. 1, p. 1, doi. 10.1186/1757-2215-6-2

By:

Gunn, Shelly;
Reveles, Xavier;
Weldon, Korrie;
Barrera, Andres;
Ishaque, Mariam;
Taylor, Dale;
McCaskill, Chris;
Kim, Jaeweon;
Shah, Rashmi;
Mohammed, Mansoor;
Barry, Todd;
Kaiser, Brianne;
Patnaik, Amita;
Tolcher, Anthony

Publication type:

Article

Changes of lung tumour volume on CT - prediction of the reliability of assessments.

Published in:

2015

By:

Beaumont, Hubert;
Souchet, Simon;
Labatte, Jean Marc;
Iannessi, Antoine;
Tolcher, Anthony William

Publication type:

journal article

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors.

Published in:

2020

By:

Tolcher, Anthony W.;
Kurzrock, Razelle;
Valero, Vincente;
Gonzalez, Rene;
Heist, Rebecca S.;
Tan, Antoinette R.;
Means-Powell, Julie;
Werner, Theresa L.;
Becerra, Carlos;
Wang, Chenxi;
Leonowens, Cathrine;
Kalyana-Sundaram, Shanker;
Kleha, Joseph F.;
Gauvin, Jennifer;
D'Amelio, Anthony M.;
Ellis, Catherine;
Ibrahim, Nageatte;
Yan, Li;
D'Amelio, Anthony M Jr

Publication type:

journal article

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Published in:

2017

By:

Infante, Jeffrey;
Patnaik, Amita;
Verschraegen, Claire;
Olszanski, Anthony;
Shaheen, Montaser;
Burris, Howard;
Tolcher, Anthony;
Papadopoulos, Kyriakos;
Beeram, Muralidhar;
Hynes, Scott;
Leohr, Jennifer;
Lin, Aimee;
Li, Lily;
McGlothlin, Anna;
Farrington, Daphne;
Westin, Eric;
Cohen, Roger;
Infante, Jeffrey R;
Verschraegen, Claire F;
Olszanski, Anthony J

Publication type:

journal article

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.

Published in:

2016

By:

Munasinghe, Wijith;
Stodtmann, Sven;
Tolcher, Anthony;
Calvo, Emiliano;
Gordon, Michael;
Jalving, Mathilde;
Vos-Geelen, Judith;
Medina, Diane;
Bergau, Dennis;
Nuthalapati, Silpa;
Hoffman, David;
Shepherd, Stacie;
Xiong, Hao;
de Vos-Geelen, Judith

Publication type:

journal article

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Published in:

2016

By:

Patnaik, Amita;
Tolcher, Anthony;
Papadopoulos, Kyriakos;
Beeram, Murali;
Rasco, Drew;
Werner, Theresa;
Bauman, John;
Scheuber, Anita;
Cox, Donna;
Patel, Bela;
Zhou, YanYan;
Hamid, Mohammed;
Schramek, Daniel;
Sharma, Sunil;
Papadopoulos, Kyriakos P;
Werner, Theresa L;
Bauman, John W;
Cox, Donna S;
Patel, Bela R

Publication type:

journal article

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 76, n. 3, p. 587, doi. 10.1007/s00280-015-2830-8

By:

Patnaik, Amita;
Tolcher, Anthony;
Beeram, Murali;
Nemunaitis, John;
Weiss, Glen;
Bhalla, Kapil;
Agrawal, Manish;
Nichols, Gwen;
Middleton, Steven;
Beryozkina, Anna;
Sarapa, Nenad;
Peck, Richard;
Zhi, Jianguo

Publication type:

Article

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.

Published in:

Cancer Chemotherapy & Pharmacology, 2015, v. 75, n. 1, p. 183, doi. 10.1007/s00280-014-2615-5

By:

Tolcher, Anthony;
Patnaik, Amita;
Papadopoulos, Kyriakos;
Rasco, Drew;
Becerra, Carlos;
Allred, Alicia;
Orford, Keith;
Aktan, Gursel;
Ferron-Brady, Geraldine;
Ibrahim, Nageatte;
Gauvin, Jennifer;
Motwani, Monica;
Cornfeld, Mark

Publication type:

Article

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 74, n. 1, p. 77, doi. 10.1007/s00280-014-2479-8

By:

Mahalingam, Devalingam;
Malik, Laeeq;
Beeram, Muralidhar;
Rodon, Jordi;
Sankhala, Kamalesh;
Mita, Alain;
Benjamin, Daniel;
Ketchum, Norma;
Michalek, Joel;
Tolcher, Anthony;
Wright, John;
Sarantopoulos, John

Publication type:

Article

Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors.

Published in:

2014

By:

Mita, Monica;
Gordon, Michael;
Rosen, Lee;
Kapoor, Nirmal;
Choy, Gavin;
Redkar, Sanjeev;
Taverna, Pietro;
Oganesian, Aram;
Sahai, Amarpal;
Azab, Mohammad;
Bristow, Robert;
Tolcher, Anthony

Publication type:

Report

A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 363, doi. 10.1007/s00280-013-2361-0

By:

Tolcher, Anthony;
Rodrigueza, Wendi;
Rasco, Drew;
Patnaik, Amita;
Papadopoulos, Kyriakos;
Amaya, Alex;
Moore, Timothy;
Gaylor, Shari;
Bisgaier, Charles;
Sooch, Mina;
Woolliscroft, Michael;
Messmann, Richard

Publication type:

Article

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 6, p. 1499, doi. 10.1007/s00280-013-2149-2

By:

Patnaik, Amita;
Papadopoulos, Kyriakos;
Tolcher, Anthony;
Beeram, Muralidhar;
Urien, Saïk;
Schaaf, Larry;
Tahiri, Sanaa;
Bekaii-Saab, Tanios;
Lokiec, François;
Rezaï, Keyvan;
Buchbinder, Aby

Publication type:

Article

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 4, p. 1041, doi. 10.1007/s00280-013-2099-8

By:

Sandhu, Shahneen;
Papadopoulos, Kyri;
Fong, Peter;
Patnaik, Amita;
Messiou, Christina;
Olmos, David;
Wang, George;
Tromp, Brenda;
Puchalski, Thomas;
Balkwill, Frances;
Berns, Birge;
Seetharam, Shobha;
Bono, Johann;
Tolcher, Anthony

Publication type:

Article

A phase I, first-in-human dose-escalation study of amuvatinib, a multi-targeted tyrosine kinase inhibitor, in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 2, p. 463, doi. 10.1007/s00280-012-2019-3

By:

Tibes, Raoul;
Fine, Gil;
Choy, Gavin;
Redkar, Sanjeev;
Taverna, Pietro;
Oganesian, Aram;
Sahai, Amarpal;
Azab, Mohammad;
Tolcher, Anthony

Publication type:

Article

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2012, v. 70, n. 4, p. 567, doi. 10.1007/s00280-012-1942-7

By:

Lush, Richard;
Patnaik, Amita;
Sullivan, Daniel;
Papadopoulos, Kyriakos;
Trucksis, Michele;
McCrea, Jacqueline;
Cerchio, Kristine;
Li, Xiaodong;
Stroh, Mark;
Selverian, Diana;
Orford, Keith;
Ebbinghaus, Scot;
Agrawal, Nancy;
Iwamoto, Marian;
Wagner, John;
Tolcher, Anthony

Publication type:

Article

Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.

Published in:

2012

By:

Berk, Lori;
Mita, Monica;
Kreisberg, Jeff;
Bedrosian, Camille;
Tolcher, Anthony;
Clackson, Tim;
Rivera, Victor

Publication type:

Report

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 6, p. 1565, doi. 10.1007/s00280-011-1639-3

By:

Saif, Muhammad;
Sarantopoulos, John;
Patnaik, Amita;
Tolcher, Anthony;
Takimoto, Chris;
Beeram, Murali

Publication type:

Article

A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 68, n. 4, p. 959, doi. 10.1007/s00280-011-1565-4

By:

Ricart, Alejandro;
Ashton, Edward;
Cooney, Matthew;
Sarantopoulos, John;
Brell, Joanna;
Feldman, Maria;
Ruby, Kale;
Matsuda, Kazuko;
Munsey, Mark;
Medina, Gerardo;
Zambito, Angela;
Tolcher, Anthony;
Remick, Scot

Publication type:

Article

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Published in:

Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 751, doi. 10.1007/s00280-010-1372-3

By:

Tolcher, Anthony;
Appleman, Leonard;
Shapiro, Geoffrey;
Mita, Alain;
Cihon, Frank;
Mazzu, Arthur;
Sundaresan, Pavur

Publication type:

Article

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 65, n. 1, p. 167, doi. 10.1007/s00280-009-1020-y

By:

Chia-Chi Lin;
Beeram, Muralidhar;
Rowinsky, Eric K.;
Takimoto, Chris H.;
Ng, Chee M.;
Geyer Jr., Charles E.;
Denis, Louis J.;
De Bono, Johann S.;
Hao, Desiree;
Tolcher, Anthony W.;
Rha, Sun-Young;
Jolivet, Jacques;
Patnaik, Amita

Publication type:

Article

Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.

Published in:

Cancer Chemotherapy & Pharmacology, 2009, v. 63, n. 6, p. 1065, doi. 10.1007/s00280-008-0811-x

By:

Chia-Chi Lin;
Calvo, Emiliano;
Papadopoulos, Kyriakos P.;
Patnaik, Amita;
Sarantopoulos, John;
Mita, Alain C.;
Preston, Glenn G.;
Mita, Monica M.;
Rodon, Jordi;
Mays, Theresa;
I.-Tien Yeh;
O'Rourke, Pat;
Takimoto, Chris H.;
Dancey, Janet E.;
Chen, Helen;
Tolcher, Anthony W.

Publication type:

Article

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 5, p. 911, doi. 10.1007/s00280-007-0672-8

By:

Rodon, Jordi;
Garrison, Mitchell;
Hammond, Lisa A.;
de Bono, Johann;
Smith, Lon;
Forero, Leonardo;
Hao, Desirée;
Takimoto, Chris;
Lambert, John M.;
Pandite, Lini;
Howard, Maria;
Hongsheng Xie;
Tolcher, Anthony W.

Publication type:

Article

Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.

Published in:

Cancer Chemotherapy & Pharmacology, 2008, v. 62, n. 1, p. 97, doi. 10.1007/s00280-007-0579-4

By:

Guo, Feng;
Letrent, Stephen P.;
Munster, Pamela;
Britten, Carolyn D.;
Gelmon, Karen;
Tolcher, Anthony W.;
Sharma, Amarnath

Publication type:

Article

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.

Published in:

Cancer Chemotherapy & Pharmacology, 2007, v. 59, n. 2, p. 165, doi. 10.1007/s00280-006-0255-0

By:

Mita, Monica M.;
Rowinsky, Eric K.;
Forero, Leonardo;
Eckhart, S. Gail;
Izbicka, Elzbieta;
Weiss, Geoffrey R.;
Beeram, Muralidhar;
Mita, Alain C.;
de Bono, Johann S.;
Tolcher, Anthony W.;
Hammond, Lisa A.;
Simmons, Paul;
Berg, Kristin;
Takimoto, Chris;
Patnaik, Amita

Publication type:

Article

RESPONSE.

Published in:

JNCI: Journal of the National Cancer Institute, 2001, v. 93, n. 15, p. 1175

By:

Tolcher, Anthony;
Crawford, E. David;
Eisenberger, Mario;
Moinpour, Carol M.

Publication type:

Article

Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.

Published in:

2000

By:

Miayake, Hideaki;
Tolcher, Anthony;
Miayake, H;
Tolcher, A;
Gleave, M E

Publication type:

journal article

Lack of Meaningful Effect of Ridaforolimus on the Pharmacokinetics of Midazolam in Cancer Patients: Model Prediction and Clinical Confirmation.

Published in:

Journal of Clinical Pharmacology, 2014, v. 54, n. 11, p. 1256, doi. 10.1002/jcph.331

By:

Stroh, Mark;
Talaty, Jennifer;
Sandhu, Punam;
McCrea, Jacqueline;
Patnaik, Amita;
Tolcher, Anthony;
Palcza, John;
Orford, Keith;
Breidinger, Sheila;
Narasimhan, Narayana;
Panebianco, Deborah;
Lush, Richard;
Papadopoulos, Kyriakos P.;
Wagner, John A.;
Trucksis, Michele;
Agrawal, Nancy

Publication type:

Article

Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data.

Published in:

Journal of Clinical Pharmacology, 2013, v. 53, n. 10, p. 1020, doi. 10.1002/jcph.140

By:

Fetterly, Gerald J.;
Aras, Urvi;
Meholick, Patricia D.;
Takimoto, Chris;
Seetharam, Shobha;
McIntosh, Thomas;
de Bono, Johann S.;
Sandhu, Shahneen K.;
Tolcher, Anthony;
Davis, Hugh M.;
Zhou, Honghui;
Puchalski, Thomas A.

Publication type:

Article

Evaluation of the Effects of Food on the Single-Dose Pharmacokinetics of Trametinib, a First-in-Class MEK Inhibitor, in Patients with Cancer.

Published in:

Journal of Clinical Pharmacology, 2013, v. 53, n. 9, p. 946, doi. 10.1002/jcph.115

By:

Cox, Donna S.;
Papadopoulos, Kyri;
Fang, Lei;
Bauman, John;
LoRusso, Patricia;
Tolcher, Anthony;
Patnaik, Amita;
Pendry, Carolyn;
Orford, Keith;
Ouellet, Daniele

Publication type:

Article

First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.

Published in:

Journal of Hematology & Oncology, 2016, v. 9, p. 1, doi. 10.1186/s13045-016-0254-5

By:

Tianhong Li;
LoRusso, Patricia;
Maitland, Michael L.;
Ou, Sai-Hong Ignatius;
Bahceci, Erkut;
Ball, Howard A.;
Jung Wook Park;
Yuen, Geoffrey;
Tolcher, Anthony

Publication type:

Article

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors.

Published in:

Journal of Hematology & Oncology, 2014, v. 7, n. 1, p. 3, doi. 10.1186/1756-8722-7-1

By:

Rhoda Molife, L.;
Li Yan;
Vitfell-Rasmussen, Joanna;
Zernhelt, Adriane M.;
Sullivan, Daniel M.;
Cassier, Philippe A.;
Eric Chen;
Biondo, Andrea;
Tetteh, Ernestina;
Siu, Lillian L.;
Patnaik, Amita;
Papadopoulos, Kyriakos P.;
De Bono, Johann S.;
Tolcher, Anthony W.;
Minton, Susan

Publication type:

Article

A First‐in‐Human Phase I Study of OPB‐111077, a Small‐Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers.

Published in:

Oncologist, 2018, v. 23, n. 6, p. 658, doi. 10.1634/theoncologist.2017-0325

By:

Tolcher, Anthony;
Flaherty, Keith;
Shapiro, Geoffrey I.;
Berlin, Jordan;
Witzig, Thomas;
Habermann, Thomas;
Bullock, Andrea;
Rock, Edwin;
Elekes, Agnes;
Lin, Chester;
Kostic, Dusan;
Ohi, Naoto;
Rasco, Drew;
Papadopoulos, Kyriakos P.;
Patnaik, Amita;
Smith, Lon;
Cote, Gregory M.

Publication type:

Article

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.

Published in:

Nature, 2010, v. 464, n. 7291, p. 1067, doi. 10.1038/nature08956

By:

Davis, Mark E.;
Zuckerman, Jonathan E.;
Choi, Chung Hang J.;
Seligson, David;
Tolcher, Anthony;
Alabi, Christopher A.;
Yun Yen;
Heidel, Jeremy D.;
Ribas, Antoni

Publication type:

Article

A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.

Published in:

2017

By:

Bendell, Johanna C;
Javle, Milind;
Bekaii-Saab, Tanios S;
Finn, Richard S;
Wainberg, Zev A;
Laheru, Daniel A;
Weekes, Colin D;
Tan, Benjamin R;
Khan, Gazala N;
Zalupski, Mark M;
Infante, Jeffrey R;
Jones, Suzanne;
Papadopoulos, Kyriakos P;
Tolcher, Anthony W;
Chavira, Renae E;
Christy-Bittel, Janna L;
Barrett, Emma;
Patnaik, Amita

Publication type:

journal article

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3

By:

Stathis, Anastasios;
Tolcher, Anthony W.;
Wang, Judy S.;
Renouf, Daniel J.;
Chen, Lin-Chi;
Suttner, Leah H.;
Freshwater, Tomoko;
Webber, Andrea L.;
Nayak, Tapan;
Siu, Lillian L.

Publication type:

Article

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7

By:

Berlin, Jordan;
Tolcher, Anthony W.;
Ding, Cliff;
Whisenant, Jennifer G.;
Horak, Ivan D.;
Wood, Debra L.;
Nadler, Paul I.;
Hansen, Ulla Holm;
Lantto, Johan;
Skartved, Niels Jørgen Ø.;
Pedersen, Mikkel W.;
Patnaik, Amita

Publication type:

Article

A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR.

Published in:

Investigational New Drugs, 2020, v. 38, n. 5, p. 1483, doi. 10.1007/s10637-020-00908-3

By:

Cleary, James M.;
Calvo, Emiliano;
Moreno, Victor;
Juric, Dejan;
Shapiro, Geoffrey I.;
Vanderwal, Carol Ann;
Hu, Beibei;
Gifford, Maryella;
Barch, David;
Roberts-Rapp, Lisa;
Ansell, Peter J.;
Xiong, Hao;
Ocampo, Christopher;
Tolcher, Anthony W.

Publication type:

Article

A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors.

Published in:

Investigational New Drugs, 2020, v. 38, n. 1, p. 120, doi. 10.1007/s10637-019-00754-y

By:

Rosen, Lee S.;
Wesolowski, Robert;
Baffa, Raffaele;
Liao, Kai-Hsin;
Hua, Steven Y.;
Gibson, Brenda L.;
Pirie-Shepherd, Steven;
Tolcher, Anthony W.

Publication type:

Article